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Abstract
Background: Up to 70% of cancer survivors report clinically significant levels of fear of cancer recurrence (FCR).
Despite the known negative impact of FCR on psychological wellbeing and quality of life, little research has
investigated interventions for high FCR. Our team has developed and piloted a novel intervention (Conquer Fear)
based on the Self-Regulatory Executive Function Model and Relational Frame Theory and is evaluating Conquer
Fear in a randomised controlled trial (RCT). We aim to compare the efficacy and cost-efficacy of the Conquer Fear
Intervention and relaxation training in reducing the impact of FCR.
Methods/design: This study is a multi-centre RCT with 260 participants randomised either to the Conquer Fear
Intervention or relaxation training. Both interventions will be delivered in five sessions over 10 weeks by trained
psychologists, psychiatrists and social workers with five or more years experience in oncology. Conquer Fear
sessions use attentional training, detached mindfulness, meta-cognitive therapy, values clarification and
psycho-education to help patients change the way they regulate and respond to thoughts about cancer
recurrence. Relaxation training includes training in progressive and passive muscle relaxation, meditative relaxation,
visualisation and “quick relaxation” techniques. Relaxation was chosen to control for therapist time and attention
and has good face-validity as an intervention. The primary outcome is fear of cancer recurrence. Secondary
outcomes include distress, quality of life, unmet needs, and health care utilisation. Participants complete
questionnaires prior to starting the intervention, immediately after completing the intervention, 3 and 6 months
later. Eligible participants are early-stage breast or colorectal cancer survivors who have completed hospital-based
treatment between 2 months and 5 years prior to study entry and report a score in the clinical range on the Fear
of Cancer Recurrence Inventory. The biostatistician is blinded to group allocation and participants are blinded to
which intervention is being evaluated. Randomisation is computer generated, stratified by therapist, and uses
sequentially numbered sealed envelopes.
Discussion: If successful, the study will provide an evidence-based intervention to reduce psychological morbidity
in cancer survivors, and reduce overall health care costs due to more appropriate use of follow-up care and other
health services in this very large population.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12612000404820
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Background
Improved medical treatments have led to higher survival
rates for many cancers. According to recent estimates,
about 2% of the Australian population is currently living
with a diagnosis of a malignant cancer [1]. In 2004 there
were approximately 655,000 Australian cancer survivors
diagnosed with cancer during the previous 23 years [2].
In 2005, the US Institute of Medicine released a land-
mark report From Cancer Patient to Cancer Survivor:
Lost in Transition [3]. The report was critical of the pau-
city of intervention research to address the psychosocial
consequences of cancer and its treatments, and stated
that “addressing survivors’ unmet needs and providing
greater clarity around follow-up is likely to lead to sig-
nificant efficiencies in health care delivery and potential
cost savings.” [3]. One of the most prevalent unmet
needs in survivors is for help with fear of cancer recur-
rence (FCR), defined as the fear that cancer could return
or progress in the same place or another part of the
body [4]. Several large studies have found that 21-40%
of cancer survivors report a need for help dealing with
FCR [5-7].
Prevalence and trajectory of FCR
High levels of FCR are very common, with 42-70% of
survivors reporting clinically significant levels of FCR
[8,9]. Of 1442 adult cancer survivors recruited through
Australian cancer registries, 46% worried about the can-
cer returning or getting worse at 12 months post-
diagnosis [10]. Longitudinal studies of cancer survivors
show that FCR usually does not decrease over time
[11-15] even when risk of recurrence is low. This finding
is supported by two reviews including both cross-
sectional and longitudinal studies, which found little evi-
dence for a relationship between time since diagnosis
and FCR [16,17]. The enduring nature of FCR is exem-
plified by a study of long-term testicular cancer survi-
vors (average time since diagnosis 11 years), which
found that despite this population having a relatively low
risk of relapse, 24% reported FCR bothered them ‘quite a
bit’ and 7% that it bothered them ‘very much’ [18].
The importance of evidence-based treatments for FCR
FCR has a functional impact on the lives of cancer survi-
vors and their families. FCR is associated with poorer
quality of life and emotional wellbeing; higher mental
and physical fatigue; and higher depression and anxiety
in cancer survivors [17]. In a recently published study of
218 younger patients with a history of early breast can-
cer, of the 70% reporting clinical levels of FCR, 25% said
FCR considerably impaired their mood and 19% reported
it considerably impaired their ability to make plans and
set future goals [9]. Some studies have reported higher
levels of FCR in caregivers than patients [19-21].
A survey of 76 psycho-oncology health professionals
and 47 oncologists and nurses found that 30% reported
FCR was an issue for more than half their patients; 31%
of doctors reported spending more than 25% of the time
in follow-up consultations discussing FCR; 46% found
dealing with FCR challenging; and 71% were interested
in further training in how to manage FCR [22]. Despite
evidence of the relationship of FCR with psychological
morbidity and impaired quality of life, as well as a recog-
nized need from health professionals, there is a lack of
evidence-based treatments for FCR.
Additionally, a growing body of evidence suggests
there may also be significant cost savings for the health
system if FCR is effectively treated, because people with
high FCR use more services or may avoid appropriate
tests to identify recurrence in a timely fashion. The
former group increase health care use by more fre-
quently presenting for checks, whereas the latter group
may present later with a recurrence and therefore re-
quire more invasive treatments than might otherwise
have been required. Cancer patients with high FCR are:
less satisfied with their care [23], more likely to refuse
discharge from a cancer centre for follow-up [24,25],
seek readmission to a specialised cancer centre [24] and
use complementary and alternative medicines [9,26-28].
Higher FCR in young women previously diagnosed with
early breast cancer was significantly associated with less
frequent than recommended use of mammograms and
ultrasounds and more frequent visits to general
practioners [9]. Despite these findings, to date, a system-
atic analysis of the cost-implications of treating FCR has
not been conducted.
Previous interventions
To date few studies have reported an intervention spe-
cifically designed to reduce FCR. The first to appear in
the literature was a small pilot study of an intervention
(6 face-to-face individual sessions with a specialist nurse)
[29] based on the self-regulation / common sense model
of illness [30,31]. To date no outcome results from this
intervention have been published.
Three studies have reported interventions for concepts
related but not identical to FCR: fear of cancer progres-
sion [32-34]. The first evaluated an uncertainty manage-
ment intervention and the second an intervention to
reduce fear of cancer progression (including patients
with metastatic disease). However, neither had a clearly
articulated theoretical model of these concepts or the in-
terventions used to address them. Moreover, because
FCR was not specifically targeted, it was not measured
in either study, limiting their utility in this context. Both
studies demonstrated an immediate impact of the inter-
vention, but not long-term efficacy. Another non-
randomised study involving patients with mixed cancers
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and disease status has reported data on the efficacy of
two interventions to reduce fear of disease progression.
Herschbach et al. [34] assessed the impact of cognitive
behaviour group therapy and a supportive-expressive
group therapy compared to usual care. Patients were
assessed prior to the intervention, at treatment comple-
tion, and at 3 and 12 months follow-up. Both interven-
tion groups showed a significant reduction in FCR over
time compared to the control group. Patients with me-
tastases and cancer recurrence gained the most from the
interventions, suggesting that the constructs targeted
may have different meanings for disease-free individuals.
Subsequent analyses showed that patients with higher
education were more likely to have a reliable reduction
in FCR [35].
Two further studies have evaluated group therapies
designed to improve generic emotional outcomes for can-
cer survivors, where improvements in FCR were reported
as a secondary outcome. The first, [36] involving 84 breast
cancer survivors found significant reductions in FCR im-
mediately following a 6-session Mindfulness-Based Stress
Reduction group [37], but no long-term data have been
published. The second [38] reported significant reduc-
tions in FCR immediately following a 12-week Emotion
Regulation Group for breast cancer patients which in-
cluded training in guided imagery, meditation, emotional
expression, and exercises promoting control beliefs and
benefit-finding. However, improvements in FCR were not
sustained at 6 and 12 months post intervention.
In summary, very few studies have evaluated interven-
tions designed specifically to reduce FCR in patients
with mixed, early stage cancers, indicating a need for
further large, randomised controlled trials of interven-
tions to assist survivors in better managing their FCR.
Aims
The aims of this study are to evaluate in a randomised
controlled trial (RCT), the efficacy and cost efficacy of a
therapist-delivered intervention (Conquer Fear) in redu-
cing the impact of FCR in disease-free breast and colo-
rectal cancer survivors with clinical levels of FCR,
compared to a relaxation training control intervention.
Secondary aims are to evaluate patient satisfaction with
the program and the relative cost-effectiveness of
Conquer Fear and the relaxation interventions. Specific
hypotheses are that:
1. Participants in the Conquer Fear intervention will
have lower scores on the Fear of Cancer Recurrence
Inventory of at least 14.5 (0.5 standard deviation) as
compared to the attention control group (who
receive relaxation therapy) at follow-up;
2. Participants in Conquer Fear will have less cancer
specific distress, less anxiety and depression, better
quality of life, fewer unmet needs, and less
maladaptive metacognitions when compared to the
control group;
3. Patients receiving Conquer Fear will find the therapy
program useful for treating their FCR and be
satisfied with the program; and
4. The Conquer Fear intervention will be cost-effective
compared to the relaxation comparator intervention.
Methods/design
This multi-site, parallel randomised controlled trial is be-
ing led by the Psycho-Oncology Co-operative Research
Group based at the University of Sydney, Australia du-
ring 2012–2014. This project was co-funded by beyondblue,
National Breast Cancer Foundation and Cancer Australia,
and registered with the Australian New Zealand Clinical Trials
Registry with registration number ACTRN12612000404820.
Ethics approval has been obtained from the Cancer Institute
NSW Clinical Research Ethics Committee.
Participants
Therapists
Twenty therapists from 15 sites have been recruited to de-
liver the study interventions via three Australian health
professional networks: the Psycho-Oncology Co-operative
Research Group (PoCoG), the Australian Psycho-Oncology
Group and the Psychologists in Oncology Network. Thera-
pists are eligible to participate in the study if they are regis-
tered psychologists, social workers or psychiatrists with a
minimum of 5 years professional experience, and 2 years
experience in oncology settings. Participating thera-
pists are required to attend a one-day training course
involving review of both intervention manuals and prac-
tice of the intervention techniques with feedback from
senior psychologists/psychiatrists. The training course is
based on a previous workshop for therapists who
took part in the pilot study of the Conquer Fear
intervention [22].
Patients
Patients are eligible to participate if they:
 have a confirmed past diagnosis of Stage 0–2 breast
cancer or Dukes stage A-C colorectal cancer. These
diagnostic groups were selected because they are
prevalent; known to be affected by FCR [10,39,40];
have clearly defined staging to allow selection of
patients with a good prognosis and in the case of
colorectal cancer, include a mix of genders;
 are being treated with curative intent;
 have completed all hospital-based adjuvant
treatments at least 2 months and not more than
5 years prior to study entry;
 are disease free;
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 have a score in the clinical range (13 or more) on
the FCRI Severity Subscale possible range:0–36);
 are able to read and write English;
 are able to give informed consent.
Patients are ineligible if they:
 currently have severe major depression;
 currently are receiving psychological treatment from
a therapist not involved in the study;
 currently have active psychotic illness or other
psychiatric/cognitive condition.
Patients are recruited from Australian hospitals/cancer
centres at which participating therapists are employed.
The recruitment method varies between sites due to
site-specific feasibility constraints. One recruitment me-
thod is for participating therapists to approach oncolo-
gists at their site to ask them to identify potentially
eligible participants. Invitation letters printed on the
sites’ letterhead and signed by the treating oncologist are
sent to a random selection of potentially eligible patients
in small batches (n = 20) to avoid recruitment of more
participants than can be managed by the therapist. A
copy of the Severity Subscale of the Fear of Cancer Re-
currence Inventory (FCRI) and a contact details form
are included with the invitation letter for interested pa-
tients to send to the research team. A single reminder
phone call is made to all patients invited to take part in
the study if they do not respond to the invitation letter
after two weeks. Invitation letters ask patients to: con-
sider participation in the study; allow contact by the re-
searchers; complete the Severity Subscale of the FCRI to
determine their eligibility for study enrolment.
Alternatively, a study advertisement/flyer is displayed
in clinic waiting rooms, or given to patients who express
concern over their cancer coming back, by cancer nurse
coordinators, therapists (i.e. psychologists or psychia-
trists) or treating oncologists. The advertisement advises
patients interested in taking part in the study to contact
the study coordinators at the University of Sydney.
These patients are then sent a copy of the Severity
Subscale of the FCRI along with a reply-paid envelope to
return to the research team.
Following receipt of the Severity Subscale of the FCRI
the study team contacts the patients to confirm whether
they are eligible, explains the study in further detail, an-
swers any patient questions, obtains verbal consent, and
mails the information sheet and consent form along with
the baseline assessment to the patient.
Randomisation
Eligible patients who have given informed consent are
randomly assigned to receive either the Conquer Fear or
relaxation training intervention. The random allocation
sequence is generated by a biostatistician blinded to the
identity of participants and therapists, using computer-
generated random numbers. Randomisation is stratified
by therapist, with patients allocated in random blocks of
2 and 4 to enhance balance and reduce the likelihood of
researchers or therapists guessing sequence generation.
Each time an eligible patient gives informed consent to
participate in the study a sequentially numbered enve-
lope containing the patients’ group allocation will be
opened by a research co-ordinator who will then forward
this information along with the patients contact details
to the relevant participating therapist. The biostatistician
is blinded to group allocation since the randomization
list contains only A versus B and only the research co-
ordinators know to which group these refer. The partici-
pants are also blinded in that they are not aware which
is the primary intervention being evaluated.
Interventions
The theoretical framework of conquer fear
The Conquer Fear intervention is a theory-based inter-
vention developed by a PoCoG-led group including
international experts on FCR, psycho-oncology thera-
pists and researchers, medical oncologists, an exercise
physiologist, a breast physician and several consumers.
The intervention is based on Meta-cognitive Therapy
(MCT) [41], the treatment associated with the Self-
Regulation of Executive Function (S-REF) Model of
emotional disorders [42], together with components of
Acceptance and Commitment Therapy [43] to address
some of the existential issues related to experiencing a
cancer diagnosis. Regarding the latter, it is well docu-
mented that cancer survivors commonly face a crisis of
life direction: struggling with what life means to them
now, what they want to value and see as important and
how to lead a life that matters to them and those they
love.
Importantly, the S-REF model of emotional disorders
provides a mechanism by which high levels of FCR de-
velop and are maintained. It posits that a cognitive ap-
praisal system consisting of self-beliefs, knowledge and
beliefs about the benefit and uncontrollability of worry,
together with an autonomic appraisal system that evalu-
ates the perceived level of threat associated with physical
stimuli, are associated with FCR. Given cancer survivors
face a real risk of cancer recurrence, rather than directly
challenging the fears associated with a possible recur-
rence, MCT is well suited to cancer survivors as it works
at the metacognitive level teaching clients more effective
ways to respond to the presence of fears associated with
a potential cancer recurrence. More detailed information
regarding the novel theoretical formulation of FCR cre-
ated by the research team will be published elsewhere.
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The key goals of this manualised intervention are to:
 teach strategies for controlling worry and excessive
threat monitoring;
 modify underlying unhelpful beliefs about worry;
 develop appropriate monitoring and screening
behaviours;
 encourage acceptance of the uncertainty brought
about by a cancer diagnosis;
 clarify values and encourage engagement in values-
based goal setting.
The intervention is delivered in 5 x 60–90 minute, individ-
ual face-to-face sessions by a trained therapist over a period of
10 weeks (sessions are weekly/fortnightly). Each session is ac-
companied by home-based practice of skills learned in session
and home reading to consolidate skill acquisition. See Table 1.
Relaxation training
Participants randomised to the control treatment receive a 5-
session relaxation training program over a period of 10 weeks,
as detailed in Table 2. Participants receive training in progres-
sive and passive muscle relaxation, meditative relaxation,
visualisation and “quick relaxation” techniques, with regular
home-based practice and a CD for practice outside sessions.
The aim of the control condition is to provide an equivalent
amount of therapist contact to Conquer Fear, to control for
non-specific therapeutic factors (e.g. therapeutic alliance and
support), in a treatment package with face validity so that pa-
tients are not aware they are in the control condition. Rela-
xation therapy may have some beneficial effects itself.
Intervention fidelity checks
Fidelity to treatment protocols in both arms will be en-
sured by: a) having therapists submit a completed check-
list following each session; b) regular review of submitted
session checklists; c) therapist participation in monthly
group supervision; and d) recording of therapy sessions.
A random selection of 10% of recordings will be assessed
by the research team using a modified version of the re-
vised cognitive therapy scale (CTS-R; [44]). The scale
was designed to assess therapist competency in cognitive
therapy, and has good psychometric properties [44]. The
scale assesses skills specific to cognitive therapy, general
therapeutic skills including therapeutic alliance and has
Table 1 Detailed content for the conquer fear
intervention
Session Content Home based practice
1 • FCR-specific assessment; • Examine values identified in
session and devise relevant
goals (e.g. if identified value is
“being physically fit” devise
realistic ways to achieve this
and identify barriers to
achieving goal);
• Model on which treatment is
based is explained;
• Discussion of existential
changes brought about by
cancer;
• Values clarification exercise • Reflect on past experiences
and how these have shaped
response to cancer.
2 • Discuss impact of potential
vulnerability factors (e.g., past
traumatic events) on FCR;
• Practice ATT on a daily basis
throughout the remainder of
the intervention and
document in diary.
• Discuss rationale and
practice of the Attention
Training Technique (ATT), a
technique designed to help
patients reduce their
tendency to ruminate and
shift their attention more
flexibly when thoughts about
recurrence occur.
3 • Introduce the practice of
Detached Mindfulness,
designed to enhance meta-
awareness of cognition and
the ability to become an
objective observer of the
content of thoughts without
the need for evaluation or
reaction.
• Continue daily practice
of ATT;
• Practice application of
detached mindfulness on
response to thoughts which
trigger FCR.
4 • Provide information about
possible symptoms of
recurrence of breast or
colorectal cancer;
• Continue daily practice of
ATT;
• Provide guidelines to help
clients distinguish those from
benign physical complaints;
• Practice detached
mindfulness in response to
emerging thoughts about FC;
• Reassess self-examination
practices and medical
surveillance;
• Identify avoidant or
excessive behaviours;
• Devise an appropriate plan
based on best available
evidence about how to
respond to new symptoms;• Develop a behavioural
contract to help clients to
engage in recommended
levels of self-examination and
follow-up tests (if needed);
• Discuss beliefs that underpin
FCR (eg. beliefs about the
benefits of FCR, or beliefs
about physical harm caused
by FCR);
• Practice worry
postponement.
• Test the validity of these
beliefs through Socratic
dialogue.
• Introduce worry
postponement as a technique
for responding to residual
worries
Table 1 Detailed content for the conquer fear
intervention (Continued)
5 • Review goal setting task;
• Consolidate skills learned
throughout the program;
• Develop relapse prevention
plan.
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been modified to include competency in skills necessary
for the FCR intervention that are not otherwise covered
by the CTS-R. Feedback will be given where non-fidelity
is identified, as recommended by the validated ‘Method
of Assessing Treatment Delivery’ [45].
Pilot study
A pilot study of the intervention was carried out be-
tween October 2010 and December 2011 [22]. Results
are presented in detail elsewhere [22]. In brief, ten
psychologists / psychiatrists took part in a 1-day training
session held in October 2010. In post-training question-
naires, all therapists had increased knowledge about and
confidence in managing FCR. At the close of the pilot 4
therapists had recruited 8 participants (2 each). Recruit-
ment was 83% and retention rates 100%. Both patients
and therapists were highly satisfied with the interven-
tion. Patients reported finding the intervention very
helpful and had a significant and clinically meaningful
reduction in FCR as measured by the FCRI.
Outcomes
All participant outcomes are assessed using either an online
or paper and pencil self-report questionnaire containing
the measures listed below. Participants are posted or e-
mailed, as preferred, the questionnaires, to be completed
and returned in a reply-paid envelope or online. Question-
naires are completed upon enrollment in the study prior to
randomisation, immediately after treatment completion, 3
and 6 months after treatment completion. The researchers
follow up participants who do not return their question-
naire within two weeks, with up to three phone calls at dif-
ferent times of the day according to a pro forma. If phone
contact cannot be made, email and text reminders are sent
where possible. Finally, a replacement questionnaire is sent
3 weeks after the non-returned questionnaire.
Primary outcome
Fear of Cancer Recurrence is assessed using the 42-item
FCRI [39], the most comprehensive multi-dimensional
scale of FCR available, and suitable for patients with
mixed cancer diagnoses. It has been found to be internally
consistent (Chronbach’s α=0.75 to 0.91 across subscales)
and stable over a two-week interval (ρ = 0.58 to 0.83 across
subscales), and has a robust factor structure. The FCRI has
convergent validity with other standardised measures of
FCR (ρ = 0.66 to 0.77) and discriminant validity with QOL
amongst a large sample (n = 600) of Canadian cancer
patients with mixed tumours [39]. Respondents rate the
degree to which symptoms or issues affect them on a
Likert scale ranging from 0 (‘not at all’ or ‘never’) to 4 (‘a great
deal’ or ‘all the time’). Higher scores indicate higher FCR.
Secondary outcomes
 Cancer-specific distress is assessed with the 22 item
Impact of Event Scale [46] with two subscales:
intrusion and avoidance.
 General distress is assessed with the Depression,
Anxiety, Stress Scale, 21 item short form [47,48].
 Quality of life is assessed with the AQoL8D, a 35
item health-related QOL instrument that includes
domains of mental health, coping, self-worth,
happiness, relationships, along with the other
Table 2 Detailed content for the relaxation training
intervention
Session Content Home based practice
1 • Assess FCR; Practice active PMR daily
for 25 minutes
• Explain concept of stress, how it
can be adaptive when it becomes
a problem and how it can be
managed through relaxation;
• Introduce different stress
management techniques;
• Practice active progressive
muscle relation (PMR);
2 • Review active PMR and its
impact on stress levels;
Practice passive PMR daily
for 25 minutes
• Identify and resolve issues of
practicing active PMR;
• Introduce passive PMR;
• Practice passive PMR;
3 • Review passive PMR and its
impact on stress levels;
Incorporate meditative
relaxation into passive
PMR practice for
25 minutes daily• Identify and resolve issues
of practicing passive PMR;
• Introduce meditative relaxation;
• Practice meditative relaxation.
4 • Review meditative relaxation and
its impact on stress levels;
Incorporate visualisation
into passive PMR practice
for 25 minutes daily
• Identify and resolve issues
of practicing meditative relaxation;
• Introduce visualisation as a way
of shortcutting the stress
response;
• Practice visualisation.
5 • Review visualisation and its
impact on stress levels;
• Identify and resolve issues
of practicing visualisation;
• Introduce quick relaxation
techniques;
• Practice quick relaxation;
• Review skills learnt and
progress made;
• Develop plan for future practice
of relaxation techniques.
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subscales assessing functional aspects of QOL;
independent living, pain, and senses. The AQoL8D
[49,50] also allows the calculation of quality-
adjusted-life years (QALYs) through the health state
utility scoring algorithm.
 Unmet needs are assessed using the 8 item
Information sub-scale of the Survivors Unmet Needs
Survey, which includes needs relating to finding
information, knowing which information to trust
and worrying about cancer recurrence and
spread [51].
 Treatment satisfaction is evaluated using a single
question assessing overall satisfaction with the
therapy.
Exploratory outcomes
 Metacognitions (the cognitive processes, strategies,
and knowledge that are involved in the regulation
and appraisal of thinking itself.’[52]) are measured
with the Metacognitions Questionnaire-30 [52,53],
a 30 item questionnaire with 5 subscales measuring:
cognitive confidence; positive beliefs about worry;
cognitive self-consciousness; uncontrollability and
danger; and need to control thoughts.
 Fear of cancer recurrence will also be measured
using the Concerns About Recurrence
Questionnaire (CAR-Q), a 5 item purpose designed
questionnaire developed by BT and PB, to act as a
brief screen of FCR. This is to test the psychometric
properties of the CAR-Q.
Potential covariates
Clinical and demographic information will include age,
time since diagnosis, marital status, education, parity,
stage of disease, treatment received (both medical and
psychological) and current treatment (e.g. anti-depres-
sants (if any)). In addition individual level of perceived
risk of cancer recurrence will be assessed as this may in-
fluence firstly level of FCR prior to treatment and also
treatment efficacy. Other potential covariates related to
treatment are therapeutic alliance and treatment expect-
ancy and credibility. Therapeutic alliance, which has
consistently been shown to be associated with treatment
outcome [54], will be assessed using the 12-item Work-
ing Alliance Inventory short-form revised (WAI-SR)
[55]. The WAI-SR assesses the agreement on goal, the
agreement on tasks that achieve the goal, and bond be-
tween patient and therapist. Treatment expectancy,
which has been shown to predict treatment outcomes in
a variety of contexts [56], will be measured using the 6-
item Credibility/Expectancy Questionnaire [57].
Therapist measures
Training evaluation is completed by participating thera-
pists immediately after training completion. The evalu-
ation survey includes items surveying: basic demographic
features, professional qualifications and experience, con-
fidence in dealing with FCR pre- and post-training, and
satisfaction with the intervention training content and
delivery using purpose designed Likert scales. This sur-
vey was used in our previous pilot study [22].
Economic measures and analysis
Economic evaluation will be a cost-consequences analysis
conducted from both the broad societal perspective and the
narrower perspective of the health care sector. The eco-
nomic evaluation will compare any incremental costs of the
intervention (costs accrued in the intervention arm com-
pared to costs accrued in the control arm) to the full list of
incremental outcomes (including QALYs in a cost-utility
analysis). The intervention costs in the evaluation will in-
clude only the costs of intervention delivery, (excluding de-
velopment or research costs), to estimate the resource use
required if the intervention was rolled-out into practice
across Australia. The research team and provider records
will be used to determine the costs of the intervention
(screening costs, cost of intervention delivery and interven-
tion materials).
Other costs associated with each arm of the trial will be
estimated using a resource use diary. The diary will be used
to document and measure health behaviours and service
use - such as hospitalisation, other allied health consulta-
tions, use of alternative therapies and self-monitoring be-
haviours. The diary will also document days out-of-role
(including paid and unpaid work) travel costs and carer
costs. The diary will be based on existing resource use
questionnaires used in national databases and will cover
both costs paid for by the individual as well as those paid
for by third parties (such as an insurance company). Mea-
sured resource use will be valued using existing unit costs
from sources such as the Australian Refined Diagnosis Re-
lated Groups (AR-DRG). AR-DRG for costs of hospitalisa-
tion and Australian Bureau of Statistics estimates of
Australian earnings for productivity effects. Based on previ-
ous research, questionnaires have been found to be reliable
estimates of resource use [58].
Uncertainty in the cost and outcome data will be further
evaluated through nonparametric bootstrap analysis. The
sensitivity of economic evaluation results to the methods of
evaluation will be tested through sensitivity analyses,
whereby key evaluation parameters (such as unit costs), are
varied to assess the impact on the study conclusions.
Sample size
This is a longitudinal randomised controlled trial, with
one baseline measure and 3 post-intervention measures.
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The primary outcome is the Fear of Cancer Recurrence
Inventory, a 42 item scale with a possible range of 168.
We based our sample size calculation on 90% power, a
two-sided α = 0.05 t-test, dropout of 30%, a difference be-
tween groups of 14.5, and a standard deviation of 29 [39]
(a standardised effect size of 0.5). The sample size calcula-
tions should account for the clustering of outcomes by
therapist, and although there is no published intra-cluster
correlation (ICC) for the FCRI, we took guidance from
two large reviews on ICCs in similar contexts [59,60] and
used an ICC of 0.01. Assuming a total of 20 therapists,
and following Donner and Klar, [60,61] the required sam-
ple size is 13 patients per therapist, for a total of 260 pa-
tients. If dropout is lower, for example, 20% then this
sample size allows for a larger intra-cluster correlation or a
small detectable difference. This sample size also gives
90% power to detect a difference of 0.5SD between the
groups in each of the secondary outcomes. The value
includes attrition of 30%, however, we expect attrition
to be lower, since patients with FCR report a high level
of need for help, and we experienced low attrition when
piloting the intervention.
Statistical analysis
Analyses will be by intention-to-treat. Linear mixed
models will be used to account for the hierarchical, non-
independent nature of the data: repeated measures on
patients nested within therapist. A saturated time x
treatment model with unstructured covariance structure
will be used to guard against misspecification of the
model. Random effects of patient and therapist will be
used. The primary analysis will be the comparison at the
each of the 3 post-baseline (post-treatment) time points
of the two arms using a contrast within this mixed
model. Overall pattern of change will be assessed by
testing the treatment by time interaction. Adjusted ana-
lysis, including using baseline FCRI, sex, age, time since
diagnosis, cancer type, perceived risk, treatment expect-
ancy and therapeutic alliance will also be investigated.
Variables will be included in the model if they have a
Kendall’s Tau correlation higher than 0.1 with FCRI.
Mixed models yield unbiased estimates for data which
are missing completely at random and at random [62],
however, if the amount of missing data for the primary
outcome is greater than 20%, sensitivity analyses will be
performed by multiply imputing the missing data, and
adding and subtracting clinically plausible amounts from
the imputed values. These new datasets will be re-
analysed, to see how conclusions change.
Secondary outcomes (QoL, distress, unmet information
needs) will be analysed in a similar way to the primary out-
come. Treatment satisfaction and therapist training evalu-
ation will be described with descriptive statistics. To see if
colorectal and breast cancer patients responded differently
to the treatment, we will test the interaction cancer type x
treatment x time. Predictors of FCR, distress and QoL at
baseline will be explored using multiple linear regression.
The relationship between Metacognition and FCR will ex-
amined using 1) regression to see if there is a relationship
at baseline in the entire sample and then 2) using mediation
techniques following the methods of Baron and Kenny [63]
in the treatment group only, immediately post baseline
(time 1). The CAR-Q will be compared with the FCRI using
psychometric techniques.
Discussion
Theoretical significance
This RCT advances the field by representing the first con-
trolled trial of a novel, evidence-based and theoretically-
based model of psychological support for cancer survivors
with high FCR. Further, the inclusion of a health economic
evaluation will strengthen the study further. Given the
dearth of intervention research anchored in theoretical
frameworks, this trial is an important next step in filling the
gap in knowledge about how best to support this large and
growing group. Extensive preliminary research and pilot
work has demonstrated the likely success of this model.
Clinical significance
The Conquer Fear intervention aligns with emerging prior-
ities in survivorship care in cancer which identify promo-
tion of quality of life and maximizing well-being and
optimal participation in social and occupational roles as
central to care, rather than the traditional surveillance-
based approach to follow-up which focuses on identifica-
tion of new disease or late complications of cancer
treatment. It is also in line with consumer priorities for sur-
vivorship research [64]. This intervention has the potential
to reduce FCR and improve the QoL of patients, and re-
duce health care costs. The eventual goal of this study is to
distribute an evidence-based, manualised, psychological
intervention for FCR. Implementation of the Conquer Fear
intervention will therefore help to eradicate barriers to ap-
propriate psycho-social care for survivors, and has far-
reaching service and policy implications in terms of
implementing ‘best practice’ recommendations for the
ever-increasing numbers of cancer survivors.
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